PPAR-alpha/PPAR-gamma

Class

Dual PPAR-alpha/gamma agonist

PPAR-alpha and PPAR-gamma are nuclear hormone receptors, proteins that reside inside the cell nucleus and, once activated, bind DNA to change which genes are transcribed. PPAR-alpha activation primarily governs fatty acid breakdown and lipoprotein metabolism, lowering circulating triglycerides and raising protective high-density lipoprotein cholesterol. PPAR-gamma activation primarily governs fat cell differentiation and glucose handling, improving how tissues respond to insulin. Because triglyceride excess and insulin resistance frequently coexist in metabolic disease, particularly in type 2 diabetes with dyslipidemia, a single molecule engaging both receptors aims to correct lipid and glucose abnormalities together rather than requiring two separate drug classes. This dual-agonist strategy sits alongside single-target agonists that act on only PPAR-alpha (fibrates) or only PPAR-gamma (thiazolidinediones), each of which addresses one half of the metabolic picture. The broader rationale for modulating these receptors is that dyslipidemia and insulin resistance both drive cardiovascular risk over time, so intervening on the nuclear receptor pathways that regulate lipid and glucose metabolism is a longstanding therapeutic approach in metabolic and cardiometabolic disease.